| Hazard Information | Back Directory | [Uses]
Monalizumab (IPH2201) is a potentially first-in-class immune checkpoint
inhibitor targeting NKG2A receptors expressed on tumor infiltrating
cytotoxic CD8+ T cells and NK cells. | [Mechanism of action]
Monalizumab is a blocking antibody that prevents the inhibition of
CD8+ T cells and NK cell by tumor cells expressing HLA-E. By acting
simultaneously on innate and adaptive immunity, monalizumab may
re-establish a broad anti-tumor response. | [in vivo]
Monalizumab (50 ?μg, intratumoral injections, together with 8?millions of activated NK cells) effectively inhibits tumor growth in xenografted HLA-E+ tumors in immunodeficient mice[4].
| Animal Model: | immunodeficient mice xenografted with Cal-27 HLA-E high tumor cell[4] | | Dosage: | 50?μg, together with 8?millions of activated NK cells | | Administration: | intratumoral injections | | Result: | Shows a synergestic antitumor effect.
Enhanced NK-cell killing, and induces lysis of tumor cells. |
|
|
| Company Name: |
Biolab Reagents
|
| Tel: |
027-65279366 18108604356 |
| Website: |
www.biolabreagent.com/ |
|